Small molecule · developed by Lakefront Biotherapeutics NV
GLPG1205 is an oral drug given as a hard gelatin capsule. It is studied in idiopathic pulmonary fibrosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03725852 | Phase 2 | Idiopathic Pulmonary Fibrosis | Completed | LKFT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Idiopathic Pulmonary Fibrosis
Updated Oct 18, 2026. Something wrong or missing? Report it on the LKFT page.
See LKFT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LKFT catalysts and pipeline →